Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(27 sites) United States
UCSF Medical Center at Mission Bay ( Site 5008), San Francisco, California Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026), Mineola, New York Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York, New York Memorial Sloan Kettering Cancer Center ( Site 5002), New York, New York Duke Cancer Institute ( Site 5015), Durham, North Carolina UPMC Cancer Center/Hillman Cancer Center ( Site 5017), Pittsburgh, Pennsylvania Chile
Centro de Estudios Clínicos SAGA ( Site 6110), Santiago, Region M. de Santiago Bradfordhill ( Site 6101), Santiago, Region M. de Santiago France
C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203), Strasbourg, Bas-Rhin Institut Claudius Regaud ( Site 5200), Toulouse, Haute-Garonne Centre Eugene Marquis ( Site 5205), Rennes, Ille-et-Vilaine Institut De Cancerologie De Lorraine ( Site 5204), Vandœuvre-lès-Nancy, Meurthe-et-Moselle Gustave Roussy ( Site 5202), Villejuif, Île-de-France Region Israel
Rambam Health Care Campus ( Site 5500), Haifa Rabin Medical Center ( Site 5502), Petah Tikva Sheba Medical Center ( Site 5501), Ramat Gan Sourasky Medical Center ( Site 5503), Tel Aviv Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 6201), Bydgoszcz, Kuyavian-Pomeranian Voivodeship Uniwersyteckie Centrum Kliniczne ( Site 6202), Gdansk, Pomeranian Voivodeship South Korea
Severance Hospital ( Site 5802), Seoul Asan Medical Center ( Site 5800), Seoul Samsung Medical Center ( Site 5801), Seoul Spain
Hospital Universitario Ramon y Cajal ( Site 5301), Madrid, Madrid, Comunidad de Hospital Universitari Vall d'Hebron ( Site 5300), Barcelona United Kingdom
Western General Hospital ( Site 5402), Edinburgh, Edinburgh, City of St Bartholomew's Hospital ( Site 5401), London, London, City of The Christie NHS Foundation Trust ( Site 5400), Manchester